MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from exercise of
options
$10,414K
Proceeds from exercise of
warrants
$651K
Net cash provided by
financing activities
$11,065K
Net change in cash,
cash equivalents and...
-$31,048K
Canceled cashflow
$11,065K
Share-based compensation
$18,002K
Changes in prepayments
and other...
-$15,219K
Foreign exchange
(gains)/losses
-$1,613K
Depreciation and
amortization
$62K
Loss on disposal of
property, plant and...
-$12K
Amortization of
premium/discount on...
$10K
Maturities of marketable
securities
$51,000K
Net cash used in
operating activities
-$30,604K
Net cash (used
in)/provided by investing...
-$11,509K
Canceled cashflow
$34,918K
Canceled cashflow
$51,000K
Loss for the period
-$48,441K
Purchases of marketable
securities
$62,471K
Changes in accrued
expenses and other...
-$10,330K
Fair value change -
derivative earnout and...
-$5,942K
Changes in accounts
payable
-$793K
Non-cash rent expense
-$19K
Purchase of property,
plant and equipment,...
$38K
Back
Back
Cash Flow
NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS)
source: myfinsight.com